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Introduction 
Ependymoma is the third most common pediatric brain tumor [1]. 
Thirty percent of all pediatric ependymomas occur in children be-
low 3 years of age [2]. The 7-year local control and event-free 
survival rates in pediatric ependymoma patients undergoing cur-
rent treatment regimens (maximal safe resection, followed by fo-
cal adjuvant radiotherapy [RT]) were reported to be 83.7% and 
69.1%, respectively [3]. In particular, both progression-free surviv-
al (PFS) and overall survival (OS) were significantly worse in pa-
tients with anaplastic ependymoma (grade III) than in patients 
with grade II ependymoma [4]. 
Although RT is indispensable for the prevention of local recur-
rence of anaplastic ependymoma, the exposure of normal tissue to 
radiation may lead to acute or late toxicity. There are many reports 
of long-term sequelae of central nervous system (CNS) tumors, 
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Purpose: Intensity-modulated radiotherapy (IMRT) allows for more precise treatment, reducing un-
wanted radiation to nearby structures. We investigated the safety and feasibility of IMRT for anaplas-
tic ependymoma patients below 3 years of age. 
Materials and Methods: A total of 9 anaplastic ependymoma patients below 3 years of age, who re-
ceived IMRT between October 2011 and December 2017 were retrospectively reviewed. The median 
equivalent dose in 2 Gy fractions was 52.0 Gy (range, 48.0 to 60.0 Gy). Treatment outcomes and neu-
rologic morbidities were reviewed in detail. 
Results: The median patient age was 20.9 months (range, 12.1 to 31.2 months). All patients under-
went surgery. The rates of 5-year overall survival, freedom from local recurrence, and progression-free 
survival were 40.6%, 53.3%, and 26.7%, respectively. Of the 9 patients, 5 experienced recurrences (3 
had local recurrence, 1 had both local recurrence and cerebrospinal fluid [CSF] seeding, and 1 had 
CSF seeding alone). Five patients died because of disease progression. Assessment of neurologic mor-
bidity revealed motor dysfunction in 3 patients, all of whom presented with hydrocephalus at initial 
diagnosis because of the location of the tumor and already had neurologic deficits before radiothera-
py (RT). 
Conclusion: Neurologic morbidity is not caused by RT alone but may result from mass effects of the 
tumor and surgical sequelae. Administration of IMRT to anaplastic ependymoma patients below 3 
years of age yielded encouraging local control and tolerable morbidities. High-precision modern RT 
such as IMRT can be considered for very young patients with anaplastic ependymoma. 
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such as neurocognitive dysfunctions, growth disorders, psycholog-
ical and behavioral disorders, ototoxicity, and increased risk of 
secondary malignancy [5-7]. On the basis of this evidence, many 
physicians try and avoid RT in children below 3 years of age who 
are particularly vulnerable to the damaging effects of radiation. 
Despite concerns regarding RT-related toxicity, there is an 
emerging need for adjuvant RT in patients below 3 years of age 
with CNS tumors. The prospective German brain tumor trials HIT-
SKK 87 and 92 [8] evaluated the role of RT in anaplastic ependy-
moma in children below 3 years of age and showed that delaying 
RT increased the risk of local recurrence even after intensive che-
motherapy. In addition, according to the Children’s Oncology 
Group trial (ACNS0121) [9], the effectiveness of chemotherapy is 
not yet clear and thus extensive delays in or avoidance of adjuvant 
RT should be avoided. 
Recent developments in RT technology, such as intensity-modu-
lated radiotherapy (IMRT), have led to more accurate and precise 
treatments than the three-dimensional conformal radiotherapy 
(3D-CRT) plans (Fig. 1), thereby reducing unnecessary radiation 
exposure of surrounding normal tissues. As shown on the dose 
Fig. 1. Comparison of three-dimensional conformal radiotherapy (A) versus intensity-modulated radiotherapy (B) in the treatment of brain tu-
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volume histogram, there was a sharp reduction in the planning 
target volume (PTV) in the IMRT plan, representing the superior 
PTV dose homogeneity (Fig. 2). Moreover, dose-volume histograms 
showed a lower dose to the optic chiasm, brainstem, and both co-
chleae on IMRT, demonstrating that RT-related neurologic toxicity 
can be significantly reduced. 
The aim of this study was to evaluate the safety and feasibility 
of IMRT in children under 3 years of age who received IMRT for 
anaplastic ependymoma. 
Materials and Methods 
1. Patient selection 
Patients below 3 years of age with anaplastic ependymoma who 
underwent postoperative IMRT at our institution between October 
2011 and December 2017 were included in this study. All patients 
were diagnosed on the basis of histological confirmation and un-
derwent magnetic resonance imaging (MRI) for disease evaluation 
and follow-up. Pathology was confirmed by surgical resection. A 
total of 9 patients were included in our study. This study was ap-
proved by the Institutional Review Board of the Yonsei University 
Health System (No. 4-2019-0939). The informed consent was 
waived by Institutional Review Board. 
2. Follow-up and assessment of neurologic morbidity 
During the RT period, patients were followed up clinically once a 
week. After RT, patients were followed up clinically within 1 
month, then every 3 months for the first 2 years, every 6 months 
for 1 year, and once a year thereafter. MRI examination was also 
performed 1 month after RT, followed by every 3 months for the 
first year, every 6 months for next 2 years, and once a year there-
after. Recurrence was determined by comprehensive evaluation of 
MRI images and clinical findings. 
Three categories related to neurologic morbidity (neurocognitive 
Fig. 2. Comparison of dose volume histograms between three-dimensional conformal radiotherapy (dotted line) and intensity-modulated radio-
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dysfunction, motor dysfunction, and hearing impairment) were 
retrospectively evaluated through medical records maintained by 
physiatrists, pediatric neurosurgeons, pediatric medical oncolo-
gists, and pediatric radiation oncologists as well as using the Den-
ver Developmental Screening Test II (DDST-II) and the Bayley 
Scales of Infant and Toddler Development. The DDST-II is a revised 
version of the Denver Developmental Screening Test designed to 
identify developmental problems in children aged 0–6 years; it is 
divided into four areas: personal-social, fine motor-adaptive, lan-
guage, and gross motor [10]. The Bayley Scales of Infant and Tod-
dler Development (Bayley-III is the current version) are a standard 
series of measurements primarily used to assess the development 
of infants and toddlers aged 1–42 months [11]. Neurocognitive 
dysfunction was defined as the occurrence of declining intellectu-
al function or of problems with attention, processing speed, or 
working memory [12]. Because treatment and clinical features 
were different for each patient, each patient’s record was re-
viewed in detail by radiation oncologists (JL, HIY, and COS) and a 
neurosurgeon (DSK) to analyze the exact causes of neurologic 
morbidity. 
3. Radiotherapy 
All patients underwent simulation computed tomography (CT) for 
RT planning. During simulation CT, the patient’s head and neck 
were immobilized with a thermoplastic mask in the supine posi-
tion. Simulation CT images were imported into MIM software 
(MIM Software Inc., Cleveland, OH, USA) for target delineation. 
Gross tumor volume 1 (GTV1) consisted of any residual or recur-
rent lesions. GTV2 was defined as GTV1 plus the surgical cavity. 
Clinical target volume (CTV) was defined as GTV2 plus 0.5–1.0 cm 
margins. PTV was defined as the CTV plus 0.3 cm margins. The To-
moTherapy (Accuray, Sunnyvale, CA, USA) or RayStation (RaySe-
arch Laboratories, Stockholm, Sweden) software was used for 
IMRT plans. In an IMRT plan, higher doses were prescribed in the 
order of GTV1, GTV2, and CTV using a simultaneous-integrated 
boost technique. The median total dose of GTV1, GTV2, and CTV 
was equivalent to a dose of 2 Gy fractions (EQD2) 57.0 Gy (range, 
56.0 to 60.0 Gy, α/β =  3), 52.0 Gy (range, 48.0 to 60.0 Gy, α/β =  3), 
and 40.0 Gy (range, 38.0 to 52.0 Gy, α/β =  3), respectively (Table 1). 
If the patient was unable to fall asleep during RT, we attempted 
conscious sedation by administering 25–100 mg/kg chloral hy-
drate orally. In cases wherein chloral hydrate failed, we adminis-
tered 0.05–0.1 mg/kg midazolam intravenously. If the second op-
tion also failed, we attempted general anesthesia by administrat-
ing propofol. Of our 9 patients, 2 went to sleep before RT, 3 were 
under conscious sedation with chloral hydrate, 1 was sedated with 
midazolam because of failure of chloral hydrate, and the other 3 
were treated under general anesthesia with propofol. 
4. Statistical analysis 
OS is calculated from the date of RT to the date of death, regard-
less of the cause of death. Local recurrence is defined as recur-
rence within the RT field. Freedom from local recurrence (FFLR) is 
defined as the time from the date of RT to local recurrence. PFS is 
defined as the time from the date of RT to any recurrence or 
death. Survival outcomes were analyzed using the Kaplan-Meier 
method and log-rank test. Statistical analyses were performed us-
ing IBM SPSS version 23.0 software (IBM Corp., Armonk, NY, USA). 
Results 
1. Patient and treatment characteristics 
The baseline and treatment characteristics of all 9 patients are 
listed in Table 1. The median patient age was 20.9 months (range, 
12.1 to 31.2 months). Five patients were male and 4 were female. 
The median tumor size was 5.1 cm (range, 2.4 to 7.0 cm). The most 
common tumor location was the 4th ventricle (6 patients, 66.7%), 
and the remaining tumors were located in the cerebellopontine 
angle cistern, temporo-parieto-occipital lobe, or frontal lobe. When 
Table 1. Patient and treatment characteristics
Characteristic Value
Age (mo) 20.9 (12.1–31.2)
Sex
 Male 5 (55.6)
 Female 4 (44.4)
Tumor size (cm) 5.1 (2.4–7.0)
Tumor site
 Supratentorial 2 (22.2)
 Infratentorial 7 (77.8)
Surgery
 Gross total resection 5 (55.6)
 Near total resection 2 (22.2)
 Subtotal resection 2 (22.2)
Total RT dose (Gy) (EQD2, α/β =  3)
 GTV1 57.0 (56.0–60.0)
 GTV2 52.0 (48.0–60.0)
 CTV 40.0 (38.0–52.0)
Fractional RT dose (Gy)
 GTV1 2.0 (2.0–2.1)
 GTV2 1.8 (1.8–2.0)
 CTV 1.5 (1.5–1.8)
Values are presented as median (range) or number of patients (%).
RT, radiotherapy; EQD2, equivalent dose in 2 Gy fractions; GTV, gross 
tumor volume; CTV, clinical target volume.
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the location of the tumor was divided by the tentorium cerebelli, 
the tumors were in the infratentorial area in 7 patients. 
All patients underwent surgery. Five patients underwent gross 
total resection (no residual tumor), 2 underwent near total resec-
tion (>90% of tumor removed), and 2 underwent subtotal resec-
tion (50%–90% of tumor removed) [13]. The time interval from 
surgery to RT was 20–140 days (median: 28 days). No patient re-
ceived chemotherapy or peripheral blood stem cell transplanta-
tion. All patients except one received IMRT postoperatively at ini-
tial diagnosis. The remaining patient received salvage RT because 
of recurrence after the initial surgery.  
2. Survival outcomes 
The median follow-up duration was 28.0 months (range, 19.3 to 
76.0 months). The 5-year OS, FFLR, and PFS rates for all patients 
were 40.6%, 53.3%, and 26.7%, respectively (Fig. 3A–3C). 
Recurrence occurred in 5 patients: 3 had local recurrence, 1 had 
both local recurrence and cerebrospinal fluid (CSF) seeding, and 1 
had CSF seeding alone. Four patients without recurrence had un-
dergone gross total resection and received EQD2 52– 60 Gy to the 
tumor bed. None of these 4 patients underwent additional surgery 
or chemotherapy after RT. 
Of the 3 patients who underwent local recurrence, 1 received 
surgery and adjuvant chemotherapy as salvage treatment; howev-
er, residual tumor progression was observed. The patient subse-
quently underwent surgery but died because of disease progres-
sion. The second patient underwent gamma knife surgery as sal-
vage treatment but developed CSF seeding thereafter. Despite 
subsequently undergoing palliative re-irradiation targeting the 
whole ventricle, the patient died because of disease progression. 
The third patient underwent surgery and gamma knife surgery for 
residual lesions, followed by adjuvant chemotherapy as salvage 
treatment. However, 1 year after the end of chemotherapy, a re-
current tumor was observed. Gamma knife surgery was repeated, 
but the patient died because of disease progression. 
One patient with local recurrence and CSF seeding underwent 
surgery as salvage treatment and was expected to receive adju-
vant chemotherapy; however, the treatment was delayed because 
of the patient’s poor physical condition, and the patient died be-
cause of progression of leptomeningeal seeding. 
One patient who experienced CSF seeding at the age of 6 years 
2 months was treated with tumor removal for recurrent lesions at 
the L2-L5 vertebrae of the spinal cord, followed by 36 Gy cranio-
spinal irradiation and boost RT of 18 Gy to the tumor bed. Approx-
imately 10 months after the end of RT, the patient showed no evi-
dence of disease. 
Of the 4 patients without recurrence, 2 received EQD2 52 Gy to 
the tumor bed after gross total resection of the 4th ventricle tu-
mor and 40 Gy to the tumor bed plus margins. They showed no 
evidence of disease for approximately 2 years after RT completion. 
Another patient received EQD2 56 Gy to the tumor bed after gross 
total resection of the left temporal-parietal-occipital lobe tumor 
and 52 Gy to the tumor bed plus margins. This patient showed no 
evidence of disease for 6 years after RT completion. The last pa-
tient received EQD2 60 Gy to the tumor bed after gross total re-
section of the right frontal lobe tumor and 52 Gy to the tumor bed 
plus margins. The patient showed no evidence of disease for 2 
years and 6 months after the RT completion. 
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3. Neurologic morbidity 
Neurologic morbidity after treatment was evaluated in all patients, 
3 (33.3%) of whom showed neurologic morbidity; all had motor 
dysfunction alone (Table 2). The first patient had a 5-cm-sized tu-
mor located in the 4th ventricle, causing hydrocephalus. Before di-
agnosis, the patient was able to stand with support, but at the time 
of disease diagnosis and after surgery, the patient’s motor function 
had declined, and the patient was only able to sit with support for 
1 minute. There was no difference in motor dysfunction before and 
after RT. The Denver Developmental Screening Test at 18 months of 
age showed that the development levels were those of an 
11-month-old, characterized by difficulty standing alone because 
of a decline in overall muscle strength. 
The second patient had a 5.0-cm-sized tumor located in the 4th 
ventricle, causing hydrocephalus. Hydrocephalus improved after 
surgery but was still observed. The patient showed delayed gross 
muscle development after surgery, and the Denver Developmental 
Screening Test at 18 months of age showed gross motor develop-
ment levels equivalent to those of a 14-month-old. The motor dys-
function seen before RT was maintained after RT, and the patient 
subsequently underwent rehabilitation therapy. 
The third patient had a 5.9-cm-sized tumor located in the left 
cerebellopontine angle cistern, causing hydrocephalus. There was 
no deterioration in motor function after the first surgery. However, 
left-hand weakness and overall postural tone deterioration devel-
oped with progression of the residual lesion. RT was performed on 
these residual lesions. Motor dysfunction present before RT persist-
ed after RT. The patient underwent rehabilitation therapy, but per-
sistent motor function deterioration was observed. 
Discussion and Conclusion 
In pediatric patients, the immature CNS is vulnerable to RT; there-
fore, the adverse effects of RT can be more severe than those in 
adults, which in turn may lead to problems such as delayed devel-
opment [5,14]. Some studies have suggested that RT therapy 
should be delayed or excluded as a treatment option in pediatric 
patients, instead utilizing intensive chemotherapy until the age of 
3 years, when CNS cell division is nearly complete [15,16]. Howev-
er, delays in RT can compromise oncologic outcomes [8,17]. With 
advances in RT techniques, IMRT enables a more targeted delivery, 
sparing the normal tissue and markedly reducing toxicity com-
pared to that with 3D-CRT. In our hospital, IMRT has been per-
formed in patients below 3 years of age, resulting in an improve-
ment in neurologic morbidity and treatment outcome. 
The most important issue in the treatment of ependymoma is 
that it often occurs in children below 3 years of age who are more 
vulnerable to the damaging effects of RT [18]. Some studies have 
shown a poor outcome if RT was deferred for more than 1 year af-
ter surgery and therefore recommended immediate RT, even in 
children below 3 years of age [19]. In the analysis of the HIT-SKK 
87 and 92 trials that exclusively enrolled patients below 3 years of 
age with anaplastic ependymoma, the 3-year OS was 66.7% when 
RT was administered immediately after chemotherapy, compared 
to 38.5% when RT was delayed [8]. As availability of IMRT has in-
creased, recent studies analyzing pediatric ependymoma patients 
have shown that despite a reduction in treatment volumes treat-
ment with IMRT results in favorable local control rates that do not 
increase the risk of marginal failure or neurologic toxicity com-
pared to those published historically [20,21]. Together with the re-
sults presented here, these findings reveal that the use of IMRT 
Table 2. Summary for cases of neurologic morbidity
Patient 
no. Sex
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level (at 43 
months of age)
1 month before RT
RT, radiotherapy; Sx, symptoms; F, female; M, male; CPA, cerebellopontine angle; STR, subtotal resection; NTR, near total resection; MD, motor dys-
function.
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can reduce toxicity while maximizing therapeutic outcomes for 
ependymoma patients below 3 years of age. 
Until the 2000s, it was not possible to determine the optimal 
radiation dose for ependymoma because of small cohort sizes or 
heterogeneity between studies. Although some retrospective stud-
ies have recommended RT of 45 Gy or higher at the tumor site 
[22,23], the European Association of Neuro-Oncology (EANO) 
guidelines recently recommended a postoperative RT dose of 59.4 
Gy for patients older than 18 months with World Health Organi-
zation (WHO) grade II or III ependymoma, whereas a dose of 54 
Gy was recommended for patients younger than 18 months be-
cause of neurological vulnerability [24]. Given that the studies 
that were the basis for the EANO guidelines mainly used 3D-CRT, 
in the modern era, IMRT can be safely used to administer this ra-
diation dose with lower toxicity. In the current study, the median 
total doses for residual lesions were EQD2 57.0 Gy (range, 56.0 to 
60.0 Gy) and those for the tumor cavity were EQD2 52.0 Gy 
(range, 48.0 to 60.0 Gy). Although the statistical comparison was 
difficult because of the small the number of patients, the median 
total dose of tumor cavity in patients with in-field recurrence was 
EQD2 48.0 Gy (range, 48.0 to 52.0 Gy), whereas in patients with-
out in-field recurrence, the median total dose was EQD2 54.0 Gy 
(range, 52.0 to 60.0 Gy). Thus, a sufficient radiation dose may be 
critical to achieve local control, and IMRT can be used for the ad-
ministration of high radiation doses. 
Regarding RT field, the German HIT-SKK 87 and 92 trials includ-
ed neuraxis in the RT field [8], but more recent studies defined the 
RT field as the tumor bed plus margins [3,4]. The recently revised 
the EANO guideline also recommended setting the CTV to tumor 
bed plus margins [24]. In line with previous reports, our institu-
tion’s practice also defined RT field as tumor bed plus margins. 
Radiation to critical tissues is known to be associated with the 
development of neurologic morbidity [5,14]. Previous studies that 
applied IMRT or proton therapy to brain tumors concluded that 
the use of advanced RT technique for brain tumors allows for im-
proved target conformity and better critical tissue sparing, result-
ing in lower neurologic toxicity [25-27]. Therefore, on the basis of 
multiple studies, the application of a modern RT technique is im-
portant in pediatric patients. 
In our study on very young children treated with IMRT, neuro-
logic morbidity was observed in 3 patients (Table 2), all of whom 
had tumors located around the 4th ventricle. At the time of initial 
diagnosis, these 3 patients suffered from hydrocephalus due to the 
location of the tumor. Following RT, hydrocephalus worsened in 
only 1 patient. Considering the relationship between time of onset 
and RT, we can conclude that RT was not a direct cause of the hy-
drocephalus. This patient also exhibited motor dysfunction before 
RT, which did not worsen after RT. Issues arising from pediatric 
hydrocephalus, including surgical complications, academic 
achievement, and neurologic sequelae, have been the focus of nu-
merous studies. Motor handicap in pediatric patients with hydro-
cephalus was reported in 30%–60% of cases [28-30], and low IQ 
was reported in 12.5%–54.7% of cases [31,32]. Our findings sug-
gest that most toxicities are caused by mass effects from the tu-
mor itself combined with sequelae from surgery. 
One of the limitations of this study was the small sample size, 
making statistical analysis difficult. In addition, because we did 
not conduct longitudinal studies that prospectively measured neu-
rologic deficits, it was difficult to analyze the changing patterns 
of neurologic deficiencies. Thus, although neurologic morbidity 
was thought to be caused by a combination of mass effects from 
the tumor and sequelae from surgery, it was difficult to determine 
how RT affected neurologic morbidity exactly. Despite these lim-
itations, our results are still meaningful. Few previous studies have 
collected data from this many anaplastic ependymoma patients 
below 3 years of age who received IMRT from one institution. As 
well, we tried to analyze each case in detail and compared related 
factors to the greatest extent possible. 
In conclusion, pediatric anaplastic ependymoma patients below 
the age of 3 years who received IMRT showed an encouraging lo-
cal control rate and tolerable toxicity. These outcomes were com-
parable to those of other studies. Although neurologic morbidities 
were observed in 3 patients, these appear to be caused by the tu-
mor itself and/or sequelae from surgery. On the basis of these re-
sults, when performing RT for anaplastic ependymoma in very 
young patients, a high-precision modern RT approach such as 
IMRT should be actively considered. 
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